Crossject has developed a deep pipeline of products that are based on its proprietary needle-free injection system, Zeneo, across a variety of indications, with a focus on emergency-related areas. In addition to avoiding needles, Zeneo provides a simple and quick (~1/10th of a second) delivery of the drug. Recently, the company has added Zeneo Terbutaline for the acute treatment of exacerbations in severe asthmatics. This is a large market (~2.5m in the US) in need of better choices for patients.
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.